Personal Genomics, Inc.
體學生物科技(股)公司

+886-3-5910323

+886-3-5910122

8 Shengyi Rd. Sec. 2, 4F, Zhubei, Hsinchu 30261, Taiwan

Copyright ©2019 by Personal Genomics, Inc. All Rights Reserved. Proudly created with Wix.com

Making personalized genomics a reality

Opto-Electronic Single Molecule Sequencing, our revolutionary semiconductor-based technology, enables high-throughput long-read gene sequencing at very high speeds yet very low cost, making the promise of personalized genomics a reality for all.

Social network concept

Enhancing the Art of  Sequencing

Gene sequencing allows for in-depth analysis of life’s codes in a holistic, systematic and scientific manner, and provides methods for clinical diagnosis, prevention and treatment of diseases. In addition to healthcare, there are many potential applications for gene sequencing such as pandemic control, agriculture, food safety, public security, and environmental monitoring, etc.

 

The existing uses of gene sequencing, however, are limited to only a very small group of sophisticated life sciences researchers. To unlock the great potential of gene sequencing and enable the personalized healthcare, it is necessary to further reduce its costs and enhance its speed, efficiency and functionality.

 

Opto-Electronic
Single Molecule Sequencing

Our Technology

Our revolutionary opto-electronic single  molecule sequencing technology (OES™, previously s-TOP) uses a high-density array of nano-wells and opto-electronic sensors on a semiconductor chip to carry out large-scale DNA sequencing. The system coupled with our unique 3' sequencing chemistry and proprietary enzyme can provide continuous high-accuracy long-read gene sequencing at low cost.

Our Competitive Advantages

● Simple, compact, and cost effective


● High sequencing speed


● Long and short reads 


● High accuracy

Personal Genomics owns more than 180 patents and patent applications worldwide including the United States, EU, Australia, Asian and other countries. The patent portfolio covers the OES concept, chip & system, opto-electronic detection, novel chemistry, workflow and algorithm, etc. The extensive strategic IP portfolio ensures sufficient protection and freedom of operation.

Recent Publications

ACS Nano 2019,13,4,4486-4495​

Triple-Junction Optoelectronic Sensor with Nanophotonic Layer Integration for Single-Molecule Level Decoding

Hsieh HY, Peng YH, Lin SF, et al.

Nature Communications Biology Vol. 2, Article number: 224 (2019)

Thermococcus sp. 9°N DNA polymerase exhibits 3′-esterase activity that can be harnessed for DNA sequencing

LinWu SW, Tu YH, Tsai TY, et al.

 

180+ Patents

International Teamwork

The company's primary laboratories are located in Hsinchu, in the heart of Taiwan's Silicon Valley, to effectively leverage semiconductor infrastructure and knowledge in Taiwan. The sequencing technology and product development are carried out by an experienced and interdisciplinary team, and are supported by research groups in USA, Europe and Asia.

 

Board and Management Team

Johnsee Lee, Ph.D., MBA

Founder, President & CEO, Director of the Board

Chung-Fan Chiou, Ph.D.

Founder, CTO, Director of the Board

Ding-Hua Hu, Ph.D.

Founder, Director and Chairman of the Board

Dr. Chiou is the primary inventor of PGI's OES (previously s-TOP) sequencing technology. He was the team leader of $1000 genome sequencing project at ITRI. Dr. Chiou received his Ph.D. from Purdue University. He joined ITRI in 1992, and later became the Head of Strategic Planning for Biomedical Engineering Center. He has successfully led a high-density DNA microarray project into commercialization. Dr. Chiou specializes in bio-engineering and system integration. He has extensive experiences in developing genomics technologies for life science tool markets, and has effectively completed the product development and mass production of microarray within two years. Dr. Chiou received outstanding research awards from ITRI.

Patrick Soon-Shiong, M.D.

Dr. Soon-Shiong is a physician, surgeon, and scientist who has pioneered novel therapies for both diabetes and cancer, published more than 100 scientific papers, and has more than 95 issued patents on groundbreaking advancements spanning a myriad of scientific and medical fields. Dr. Soon-Shiong serves as Chairman of the Chan Soon-Shiong Family Foundation and Chairman and CEO of the Chan Soon-Shiong Institute of Molecular Medicine, a non-profit medical research organization. He currently co-chairs the CEO

and Services organization (ERSO), CEO of H&Q in Taiwan, Chairman of Macronix, Chairman of the Taiwan Venture Capital Association, and Chairman of Chien Kung V.C. Corp., Alpha V.C. Fund, Inc. and Chien Cheng V.C. Corp. As a result, he has many former students based in Silicon Valley and a well-developed personal network and reputation in the technology communities in both Silicon Valley and Taiwan. As a President of Hambrecht & Quist Taiwan in the 1980s, he helped launch the venture-capital industry in Taiwan, fueling the boom in the high tech industry. He also founded his own venture capital firm, Chien Kung Venture Capital Corporation.

Dr. Lee is the founder and first Director of the Biomedical Engineering Center at ITRI. Dr. Lee has played a key leadership role in the development of Taiwan’s world-class high-tech industries. Dr. Lee received a Ph.D. from Illinois Institute of Technology, and an MBA from University of Chicago. He is also a graduate of Harvard Business School's Advanced Management Program. Dr. Lee held various technical and managerial positions at Argonne National Laboratories, Johnson Matthey, and ITRI. He has many years of hands-on experiences in both frontier technology research and industrial commercialization.

Dr. Hu is one of the most accomplished leaders of Taiwan’s semiconductor industry. He received his Ph.D. in electrical engineering from University of Missouri, and Master’s degree in management science from Stanford University. Dr. Hu has over 30 years of experiences in the creation and management of high-tech companies, including served of world-class companies, such as UMC, TSMC, TOSIA, Accton, etc. He also served as Managing Director for H&Q Asia, and for Champion Consulting Corporation. He was the Chairman for Macronix Corp. and for Phalanx Biotech. He has served as a Professor at Chiao-tung University, Associate Director of Industry Technology and Research Institute (ITRI), the first General Director of Electronic Research 

Director of the Board

CEO, NantWorks Group

 Council for Health and Innovation at the Bipartisan Policy Center and is a member of the Global Advisory Board of Bank of America. Dr. Soon-Shiong is an Adjunct Professor of Surgery at UCLA, a visiting Professor at the Imperial College of London, the Executive Director of the UCLA Wireless Health Institute, a board member of the California Telehealth Network, and global director for Cancer Services and Bioinformatics at Providence Health. The Friends of the National Library of Medicine has honored him with their Distinguished Medical Science Award. He was in the cover story of 2014 Forbes Magazine as the richest physician in the world.

Shahrooz Rabizadeh, Ph.D.

Director of the Board

Chief Scientific Officer, NantOmics

Dr. Rabizadeh is the Chief Scientific Officer at NantOmics, LLC and at NantBioScience, Inc. Shahrooz received his PhD degree in neuroscience at the University of California, Los Angeles and trained as a postdoctoral fellow in Molecular Biology at Massachusetts General Hospital and Genetics at Harvard Medical School. Previously, Shahrooz was the Director of Molecular Drug Discovery at Abraxis BioScience, Inc. and an Adjunct Assistant Professor of Bioengineering at the University of California, Los Angeles. Prior to Abraxis, he co-directed the Discovery Translation Unit at the Buck Institute, where he also served as an Assistant Research Professor.

Christian Zapf

Chief Business Officer, North America

Until 2017, Mr. Zapf was Vice President, Corporate Development at NantWorks, LLC, the parent organization for an ecosystem of healthcare and technology companies led by entrepreneur Dr. Patrick Soon-Shiong.  In this role, his chief responsibility was for M&A and corporate development activities.  Prior to NantWorks, from April 2006 to May 2011, he served as Vice President, Corporate Development at Abraxis BioScience, where he was responsible for corporate development, licensing and other strategic relationships.  Mr. Zapf was instrumental in the sale of Abraxis BioScience to Celgene in October 2010.   Prior to Abraxis BioScience, from December 2004 to April 2006, Mr. Zapf served as Counsel, Corporate Development at American Pharmaceutical Pharmaceuticals (APP), a company selling generic hospital injectables.  In this role, he was involved in all aspects of business development activities, including facility and plant acquisitions and supply chain relationships. Before APP, Mr. Zapf was an attorney at the Wall Street law firm of Cleary Gottlieb Steen & Hamilton LLP, where he maintained a general corporate practice.  Mr. Zapf holds a JD from Columbia University, an MBA from INSEAD and a BA from Cambridge University in the UK.

Christian Zapf, JD, MBA

Chief Business Officer, North America

Until 2017, Mr Zapf was Vice President, Corporate Development at NantWorks, LLC, the parent organization for an ecosystem of healthcare and technology companies led by entrepreneur Dr Patrick Soon-Shiong.  In this role, his chief responsibility was for M&A and corporate development activities.  Prior to NantWorks, he served as Vice President, Corporate Development at Abraxis BioScience, where he was responsible for corporate development, licensing and other strategic relationships.  Mr. Zapf was instrumental in the sale of Abraxis BioScience to Celgene in October 2010.   Prior to Abraxis BioScience, Mr. Zapf served as Counsel,

Corporate Development at American Pharmaceutical Pharmaceuticals, a company selling generic hospital injectables.  In this role, he was involved in all aspects of business development activities, including facility and plant acquisitions and supply chain relationships. Before APP, Mr. Zapf was an attorney at the Wall Street law firm of Cleary Gottlieb Steen & Hamilton LLP, where he maintained a general corporate practice.  Mr. Zapf holds a JD from Columbia University, an MBA from INSEAD and a BA from Cambridge University in the UK.

Scientific Advisory Board

Professor Lap-Chee Tsui is the President and Vice-Chancellor of the University of Hong Kong. Prior to his present appointment, Professor Tsui was Geneticist-in-Chief and Head of the Genetics and Genomic Biology Program of the Research Institute at The Hospital for Sick Children in Toronto. He was also the H.E. Sellers Chair in Cystic Fibrosis and University Professor at the University of Toronto. Professor Tsui received his Ph.D. degree from the University of Pittsburgh in 1979. After a brief research in the Oak Ridge National Laboratory, he joined the Department of Genetics at The Hospital for Sick Children. He received international acclaim 

in 1989 when he identified the defective gene that causes cystic fibrosis, which is a major breakthrough in human genetics. He has also made significant contributions to the study of the human genome, especially the characterization of chromosome 7, and identification of additional disease genes. He has 290 peer-reviewed scientific publications and 65 invited book chapters and papers. Professor Tsui has served on the editorial boards for 20 international peer-reviewed scientific journals, scientific review panels, and international committees, including the President of Human Genome Organization from 2000 to 2002.

Dr. Lu is the Founder and CEO of Etron Technology, and has co-founded several other high-tech companies. He received his M.S. and Ph.D. in Electrical Engineering from Stanford University. Dr. Lu worked for IBM and won the IBM Corporate Award. He holds over 24 U.S. patents and has published many technical papers. Dr. Lu was elected to be a Fellow of the Institute of Electrical and Electronics Engineers (IEEE). He received the IEEE Solid State Circuits Field Award and Member of National Academy of Engineering of USA. Since 1999, Dr. Lu has pioneered several Known-Good-Die Memory products enabling customers’ stacked-die system 

chips. This trend summoned the new rise of an IC Heterogeneous Integration era. Dr. Lu was awarded outstanding alumnus of National Taiwan University and the National Medal of Excellence in Science and Technology. He also serves as Chairman of the Global Semiconductor Alliance.

Yun Yen, M.D., Ph.D.

Member of Scientific Advisory Board

Dr. Yen is the Associate Director of the City of Hope Medical Center in the U.S.A. He is responsible for the institute's translational research, and co-leads the Developmental Cancer Therapeutics Program at the City of Hope. Dr. Yen received his PhD in Pathology and Cell Biology from Thomas Jefferson University. Following residency at St. Luke's Hospital, Dr. Yen completed a fellowship in the Department of Internal Medicine, Hematology, and Bone Marrow Transplantation at Yale University School of Medicine. Subsequently, he joined City of Hope as a staff physician. He is a professor in Medical Oncology and the Graduate School of Biological Sciences, as well as the Chief of Biochemical Pharmacology at the Department of Medical Oncology and Therapeutics Research. Among awards Dr. Yen received are several from the National Institutes of Health, including a prestigious fellowship while at Thomas Jefferson University. In addition, he has been awarded U.S. Army Breast Cancer and Prostate Cancer grants. The National Cancer Institute's Cancer Therapy Evaluation Program has designated his laboratory the ribonucleotide reductase Real-Time PCR Laboratory. He has published more than 140 peer-reviewed journal articles, and he serves as a reviewer/referee for several journals and on the editorial board of the Journal of Clinical Colorectal Cancer.

Hardy Chan, Ph.D.

Member of Scientific Advisory Board

Dr. Chan serves as Chief Executive Officer at Tanvex Biologics Inc. Dr. Chan co-founded ScinoPharm Taiwan Ltd. in 1997 and served as its Senior Advisor. Dr. Chan serves as a Senior Advisor to the Taiwanese government and Academia Sinica. He served as a Senior Consultant for ScinoPharm Taiwan Ltd., as the President of ScinoPharm Biotech and Chairman of ScinoPharm (Changshu) Pharmacuticals Ltd., as the President and Chief Executive Officer of ScinoPharm Kunshan, and as the Chief Scientific Officer and Executive Vice President of ScinoPharm Taiwan Ltd. He was responsible for the ScinoPharm's

Research and Development as well as Business Development. He served as the Vice President of Research and Director of Biotechnology at Syntex. He served as the Chairman of ScinoPharm Investments Ltd. and ScinoPharm (Changshu) Pharmacuticals Ltd. Dr. Chan serves as a Director of Development Center for Biotechnology and Vita Genomics Inc. He is a recipient of the distinguished Syntex's Chairman's Science Award. He has over 60 scientific manuscripts in peer-reviewed journals and three published patents. Dr. Chan holds a Ph.D in Biochemistry and a B.S in Chemistry from University of Wisconsin, Madison.

Yuh-Geng Tsay, Ph.D.

Member of Scientific Advisory Board

Dr. Tsay serves as Venture Partner at Vivo Capital, LLC since 2016. Dr. Tsay joined the firm in 2016. He served as a Senior Vice President and President of Specialty Diagnostics at Thermo Fisher Scientific Inc., since May 2008. Dr. Tsay was the President of Diagnostics at Thermo Fisher Scientific from November 2006 to May 2008. He was the founder of Diagnostics Reagents Inc. In 1987, he cofounded Yellowstone Diagnostics. He was the Group President of Immunodiagnostics at Apogent Technologies Inc. from 2000 to 2004. Dr. Tsay served as the President of Diagnostic Reagents Inc. since 1991. He served as the President of Microgenics Corporation

and also as the Executive Chairman at PharmaLegacy Laboratories (Shanghai) Co., Ltd. Dr. Tsay serves as a Board Member of PEG Bioscience. He serves as a Director of AltheaDx, Inc., Bonraybio and READCOOR, INC. He holds several patents and pioneered multiple technologies and product platforms. He has extensive experience and track record in building successful businesses that were eventually acquired or went public. He has spent his entire career in the Life Sciences space. He received the Distinguished Scholar Award from the University of Rochester (2014), and the Distinguished Alumni Awards from Cheng Kung University (2012). Dr. Tsay received his B.S. in chemistry from the National Cheng Kung University in Taiwan, his Ph.D. in Organic Chemistry from the University of Rochester.

Timothy K. Lu, M.D., Ph.D.

Member of Scientific Advisory Board

Lemelson-MIT Student Prize, Grand Prize in the National Inventor Hall of Fame’s Collegiate Inventors Competition, and the Leon Reznick Memorial Prize for “outstanding performance in research” from Harvard Medical School. He has also been selected as a Kavli Fellow by the National Academy of Sciences and a Siebel Scholar. Outside of the lab, Tim enjoys playing volleyball and tennis.

Dr. Lu received his undergraduate and M.Eng. degrees from MIT in Electrical Engineering and Computer Science. Thereafter, he obtained an M.D. from Harvard Medical School and Ph.D. from the Harvard-MIT Health Sciences and Technology Medical Engineering and Medical Physics Program. Prof. Tim Lu joined MIT as Assistant Professor at the Department. of Electrical Engineering and Computer Science in 2010 and obtained a joint appointment at the Department of Biological Engineering in 2012. Tim has won the 

Lap-Chee Tsui, OC, Ph.D.

Member of Scientific Advisory Board

Nicky C. Lu, Ph.D.

Member of Scientific Advisory Board

 

Partner with Us

Personal Genomics is committed to exceeding your needs. We are actively looking for partners in the areas below.

  • Sample Preparation

  • Sequencing Chemistry

  • Application Development

  • ​Commercialization

Contact us today if you are interested in embarking on a fulfilling and exciting partnership with us. 

8.jpg